Tabimorelin

Tabimorelin (NN703; CAS 193079-69-5; molecular formula C32H40N4O3; molecular weight 528.70) is a potent, orally active agonist of the growth hormone secretagogue receptor type 1a (GHSR1a, the ghrelin receptor), developed by Novo Nordisk as a non-injectable alternative to recombinant growth hormone therapy in adult growth hormone deficiency. The compound was derived from the selective pentapeptide growth hormone secretagogue ipamorelin (NNC 26-0161) through systematic backbone reduction and pharmacophore optimization conducted principally by Ankersen, Hansen, and colleagues in the late 1990s, yielding a tripeptide-like structure with oral bioavailability of approximately 30 percent in dogs and a plasma half-life of approximately 4.1 hours in the same species [1]. Tabimorelin binds the GHSR1a receptor and activates the Gq/11-coupled phospholipase C signaling cascade, producing calcium mobilization from intracellular stores, membrane depolarization, and pulsatile growth hormone release from anterior pituitary somatotroph cells. In single-dose Phase 1 studies in healthy male volunteers at doses of 0.05 to 12 mg/kg, the compound produced dose-dependent increases in growth hormone area under the curve and peak concentration, with significant elevations in GH AUC at 3.0 mg/kg (P = 0.027), 6.0 mg/kg (P = 0.0023), and 12 mg/kg (P < 0.0001), together with significant increases in insulin-like growth factor 1 (IGF-1) at the two highest dose levels [2]. In a 7-day repeated-dose Phase 1 study at four dose levels (1.71, 3.0, 4.5, and 6.86 mg/kg once daily), GH release remained significantly elevated above placebo on both days 1 and 7, but an overall significant decrease in GH release from day 1 to day 7 (P < 0.001) demonstrated tachyphylaxis at the somatotroph axis level [3]. IGF-1 and IGF binding protein 3 (IGFBP-3) increased at all dose levels, with significantly greater IGF-1 elevation at the three highest doses. The compound produced transient increases in prolactin and adrenocorticotropic hormone (ACTH) on day 1 that resolved by day 7, with no significant cortisol elevation on either assessment day [3]. The pivotal Phase 2 study enrolled 97 adults with confirmed growth hormone deficiency in a multicentre, randomized, double-blind, placebo-controlled design; only 9 of 83 NN703-treated patients (11 percent) achieved a serum peak GH concentration of 5 micrograms per liter or greater, and 1-week treatment did not significantly increase IGF-1, although IGFBP-3 was modestly elevated [4]. The limited clinical response was attributed to the severity of hypothalamic-pituitary axis disruption in the GH-deficient population, which depends on residual somatotroph capacity for a secretagogue mechanism to function. A separate clinical pharmacology investigation established that tabimorelin is a mechanism-based (irreversible) inhibitor of cytochrome P450 3A4, increasing midazolam AUC by 64 percent after a single dose and by 93 percent after 7 days of dosing, with persistent 45 percent elevation even after a 7-day washout [5]. This CYP3A4 liability, combined with the modest clinical efficacy in the target population and the GH tachyphylaxis on repeated dosing, led Novo Nordisk to discontinue clinical development. Tabimorelin remains a research-grade compound of interest for fundamental GHSR1a pharmacology, for structure-activity investigation within the peptidomimetic ghrelin agonist class, and as a comparator in the broader landscape of growth hormone secretagogues that includes ibutamoren (MK-0677), anamorelin, macimorelin, and capromorelin. The compound is not approved by any regulatory authority for human therapeutic use. It is supplied as a research-grade preparation by multiple chemical suppliers; investigators should obtain analytical confirmation of identity and purity on every lot.